BofA/Merrill analyst Bob Hopkins raised his price target for Inspire Medical (INSP) to $75 from $65 after the company announced that United Healthcare (UNH) will provide coverage for Inspire's obstructive sleep apnea therapy as of August 1. In a research note to investors, Hopkins, who maintains a Neutral rating on Inspire, says it takes about 2-4 months for a patient insured by United to work their way through the prior-authorization, but Inspire now estimates that it will take just five days to get approval if a patient meats the restrictions set by United. Hopkins sees potential upside to Street numbers later in 2019 and 2022, but believes his positive outlook is largely reflected in the current stock price.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here